Will patient-centric sampling become the norm for clinical trials after COVID-19?
- PMID: 33230340
- DOI: 10.1038/s41591-020-01144-1
Will patient-centric sampling become the norm for clinical trials after COVID-19?
References
- 
    - Roadcap, B. et al. Bioanalysis 12, 893–904 (2020). - DOI
 
- 
    - Vethe, N. T. et al. Ther. Drug Monit. 41, 607–614 (2019). - DOI
 
- 
    - Kovac, J. et al. J. Pharm. Biomed. Anal. 151, 339–346 (2018). - DOI
 
- 
    - Xing, J., Loureiro, J., Patel, M. T., Mikhailov, D. & Arkady, I. Bioanalysis 12, 919–935 (2020). - DOI
 
- 
    - Li, C. et al. J. Clin. Pharmacol. 58, 294–303 (2018). - DOI
 
Publication types
MeSH terms
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
 
        